Acute and chronic haemodynamic effects of naftazone in portal hypertensive rats

European Journal of Pharmacology

Volumn 344, Issue 1, 1998, Pages 37-43

  Sogni, Philippe ^a   Yang, Song ^a   Pilette, Christophe ^a   Moreau, Richard ^a   Gadano, Adrián ^a   Avenard, Gilles ^b   Bloy, Christian ^b   Lebrec, Didier ^a  

^a BEAUJON HOSPITAL   (France)

^b Laboratoires Cassenne   (France)

Author keywords

N nitro L arginine methylester (L NAME); Naftazone; Nitric oxide (NO); Portai hypertension; Prazosin; Propranolol

Indexed keywords

N(G) NITROARGININE METHYL ESTER; NAFTAZONE; NITRIC OXIDE; PRAZOSIN; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE; VASODILATATION;

ANIMALS; BLOOD PRESSURE; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; HYPERTENSION, PORTAL; MALE; NAPHTHOQUINONES; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; REGIONAL BLOOD FLOW;

EID: 0032568072     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01567-7     Document Type: Article

References (24)

1. Albillos A., Lledo J.L., Rossi I., Pérez-Paramo M., Tabuenca M.J., Banares R., Iborra J., Garrido A., Escartin P., Bosch J. Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function. Gastroenterology. 109:1995;1257-1265.
2. Berson I. Clinical study of a new venotropic drug: Mediaven (DCI Naftazone). Schweiz. Rundsch. Med. Prax. 66:1977;180-181.
3. Blanchet L., Lebrec D. Changes in splanchnic blood flow in portal hypertensive rats. Eur. J. Clin. Invest. 12:1982;327-330.
4. Bomzon A., Blendis L.M. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology. 20:1994;1343-1350.
5. Calès P., Braillon A., Jiron M.I., Lebrec D. Superior portosystemic collateral circulation estimated by azygos blood flow in patients with cirrhosis. Lack of correlation with oesophageal varices and gastrointestinal bleeding. Effect of propranolol. J. Hepatol. 1:1984;37-46.
6. Calès P., Braillon A., Girod C., Lebrec D. Acute effect of propranolol on splanchnic circulation in normal and portal hypertensive rats. J. Hepatol. 1:1985;349-357.
7. Cummings S.A., Kaumann A.J., Groszmann R.J. Comparison of the hemodynamic responses to ketanserin and prazosin in portal hypertensive rats. Hepatology. 8:1988;1112-1115.
8. Herber R., Hercelin B., Van Cantfort J., De Graeve J., Fournel-Gigleux S., Taguchi T., Magdalou J. Reduction and glucuronidation of naftazone by human and rat liver microsomes. Drug Metab. Dispos. 23:1995;1305-1314.
9. 1 and β-adrenergic antagonists and 5-hydroxytryptamine receptor antagonist on portal-systemic collateral vascular resistance in conscious rats with portal hypertension. J. Gastroenterol. Hepatol. 7:1992;449-454.
10. Lebrec, D., 1991. Animal models of portal hypertension. In: Okuda, K., Benhamou, J.P. (Eds.), Portal Hypertension: Clinical and Physiological Aspects. Springer-Verlag, Tokyo, pp. 101-113.
11. Lebrec D. Pharmacological treatment of portal hypertension: Hemodynamic effects and prevention of bleeding. Pharmacol. Ther. 61:1994;65-107.
12. Lee S.S., Girod C., Valla D., Geoffroy P., Lebrec D. Effects of pentobarbital sodium anesthesia on splanchnic hemodynamics of normal and portal-hypertensive rats. Am. J. Physiol. 249:1985;G558-G532.
13. Lee S.S., Girod C., Braillon A., Hadengue A., Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: Effect of pentobarbital sodium. Am. J. Physiol. 251:1986;G176-G180.
14. Lin H.C., Soubrane O., Cailmail S., Lebrec D. Early chronic administration of propranolol reduces the severity of portal hypertension and portal-systemic shunts in conscious portal vein stenosed rats. J. Hepatol. 13:1991;213-219.
15. Mahl, T.C., Groszmann, R.J., 1991. The pathophysiology of portal hypertension. In: Okuda, K., Benhamou, J.P. (Eds.), Portal Hypertension: Clinical and Physiological Aspects. Springer-Verlag, Tokyo, pp. 27-35.
16. Malik A.B., Kaplan J.E., Saba T.M. Reference sample method for cardiac output and regional blood flow determination in the rat. J. Appl. Physiol. 40:1976;472-475.
17. Mills P.R., Rae A.P., Farah D.A., Russel R.I., Lorimer A.R., Carter D.C. Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut. 25:1984;73-78.
18. Moncada S., Palmer R.J.M., Higgs E.A. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:1991;109-142.
19. Ouazzani J., Servy C., Bloy C., Ducrocq C. Fungal metabolite of naftazone inhibits nitrite production by activated macrophages. Biol. Med. Chem. Lett. 5:1995;1825-1828.
20. Piczueta M.P., Pique J.M., Bosch J., Whittle B.J.R., Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br. J. Pharmacol. 105:1992;184-190.
21. Pilette C., Moreau R., Sogni P., Cailmail S., Pussard E., Lebrec D. Haemodynamic and hormonal responses to long-term inhibition of nitric oxide synthesis in rats with portal hypertension. Eur. J. Pharmacol. 312:1996;63-68.
22. Sogni P., Moreau R., Ohsuga M., Cailmail S., Oberti F., Hadengue A., Pussard A.E., Lebrec D. Evidence for normal nitric oxide-mediated vasodilator tone in conscious rats with cirrhosis. Hepatology. 16:1992;980-983.
23. Sogni P., Moreau R., Gadano A., Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J. Hepatol. 23:1995;218-224.
24. Winand R. La mono-semicarbazone-2 de la naphtoquinone (DCI Naftazone) dans la maladie variqueuse. Rev. Med. Liège. 14:1977;429-431.